Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study-Reference-Cited by-同舟云学术

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study

Published:2018-03 Issue: Volume:91 Page:116-124
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Valpione Sara,Carlino Matteo S.,Mangana Johanna,Mooradian Meghan J.,McArthur Grant,Schadendorf Dirk,Hauschild Axel,Menzies Alexander M.,Arance Ana,Ascierto Paolo A.^ORCID,Di Giacomo AnnaMaria,de Rosa Francesco,Larkin James,Park John J.,Goldinger Simone M.,Sullivan Ryan J.,Xu Wen,Livingstone Elisabeth,Weichenthal Michael,Rai Rajat,Gaba Lydia,Long Georgina V.^ORCID,Lorigan Paul^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference41 articles.

1. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017;Ugurel;Eur J Cancer,2017

2. The clonal evolution of tumor cell populations;Nowell;Science,1976

3. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance;Das Thakur;Nature,2013

4. Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin beta1/FAK signaling;Hirata;Cancer Cell,2015

5. Therapy-induced tumour secretomes promote resistance and tumour progression;Obenauf;Nature,2015

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world outcomes of patients with resected stage III melanoma treated with adjuvant therapies;Cancer Medicine;2024-06

2. BRAF V600E mutation in ameloblastomas: Where are we?;Oral Surgery;2024-05-27

3. SEOM-GEM clinical guidelines for cutaneous melanoma (2023);Clinical and Translational Oncology;2024-05-15

4. Real‐world efficacy and safety of BRAF‐targeted therapy for patients with advanced melanoma: A single‐center retrospective study in Japan;The Journal of Dermatology;2024-05-08

5. Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma;European Journal of Cancer;2024-05